PRDM1 and gastric cancer: For BET inhibitors in the treatment of gastrointestinal cancers, PRDM1 in stomach cancer is one of the potential targets, and Sun et al. in 2022 reviewed the effects of BET inhibitors on gastrointestinal cancers and their advancements in clinical trials [18], while Montenegro et al. in 2016 reported that an isoxazole PNZ5 might be a potential BET inhibitor and it increased stomach cancer apoptosis even in 3D spheroid [75].